Lexicon Pharmaceuticals, Inc. (LXRX) stock
LXRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/3087% above fair value
$1.78+0.03 (+1.71%)
Close on Nov 17, 2026Market cap $792.02MP/E –Yield –
Lexicon Pharmaceuticals gross margin
Gross margin is gross profit as a percentage of revenue.
Lexicon Pharmaceuticals's gross margin for the twelve months ending Jun 30, 2026 was 99.1%. For fiscal 2025 it was 99.4%, against 98.0% the year before. The highest annual figure on record is 100.0% in fiscal 2015.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 99.4% | +1.4 |
| FY2024 | Dec 31, 2024 | 98.0% | +5.1 |
| FY2023 | Dec 31, 2023 | 92.9% | −7.1 |
| FY2022 | Dec 31, 2022 | 100.0% | +0.0 |
| FY2021 | Dec 31, 2021 | 100.0% | +8.0 |
| FY2020 | Dec 31, 2020 | 92.0% | −7.0 |
| FY2019 | Dec 31, 2019 | 99.0% | +2.9 |
| FY2018 | Dec 31, 2018 | 96.1% | −1.9 |
| FY2017 | Dec 31, 2017 | 97.9% | −2.1 |
| FY2016 | Dec 31, 2016 | 100.0% | +0.0 |
| FY2015 | Dec 31, 2015 | 100.0% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 94.4% | −5.5 |
| Q1 FY2026 | Mar 31, 2026 | 99.5% | +1.9 |
| Q4 FY2025 | Dec 31, 2025 | 96.3% | −2.3 |
| Q3 FY2025 | Sep 30, 2025 | 99.9% | +4.0 |
| Q2 FY2025 | Jun 30, 2025 | 99.9% | +10.0 |
| Q1 FY2025 | Mar 31, 2025 | 97.6% | +0.4 |
| Q4 FY2024 | Dec 31, 2024 | 98.7% | +8.7 |
| Q3 FY2024 | Sep 30, 2024 | 95.9% | +0.3 |
| Q2 FY2024 | Jun 30, 2024 | 89.9% | −7.6 |
| Q1 FY2024 | Mar 31, 2024 | 97.3% | −2.7 |
| Q4 FY2023 | Dec 31, 2023 | 90.0% | −10.0 |
| Q3 FY2023 | Sep 30, 2023 | 95.7% | −4.3 |
| Q2 FY2023 | Jun 30, 2023 | 97.5% | −2.5 |
| Q1 FY2023 | Mar 31, 2023 | 100.0% | +0.0 |
| Q4 FY2022 | Dec 31, 2022 | 100.0% | +0.0 |
| Q3 FY2022 | Sep 30, 2022 | 100.0% | +0.0 |
| Q2 FY2022 | Jun 30, 2022 | 100.0% | +0.0 |
| Q4 FY2021 | Dec 31, 2021 | 100.0% | +0.0 |
| Q3 FY2021 | Sep 30, 2021 | 100.0% | +9.5 |
| Q2 FY2021 | Jun 30, 2021 | 100.0% | +7.9 |
| Q1 FY2021 | Mar 31, 2021 | 100.0% | +7.1 |
| Q4 FY2020 | Dec 31, 2020 | 100.0% | +8.9 |
| Q3 FY2020 | Sep 30, 2020 | 90.5% | −9.3 |
| Q2 FY2020 | Jun 30, 2020 | 92.1% | +5.8 |
| Q1 FY2020 | Mar 31, 2020 | 92.9% | −1.1 |
| Q4 FY2019 | Dec 31, 2019 | 91.1% | −5.5 |
| Q3 FY2019 | Sep 30, 2019 | 99.8% | +7.7 |
| Q2 FY2019 | Jun 30, 2019 | 86.3% | −7.6 |
| Q1 FY2019 | Mar 31, 2019 | 94.0% | −3.9 |
| Q4 FY2018 | Dec 31, 2018 | 96.7% | −1.7 |
| Q3 FY2018 | Sep 30, 2018 | 92.1% | −5.7 |
| Q2 FY2018 | Jun 30, 2018 | 93.9% | −1.6 |
| Q1 FY2018 | Mar 31, 2018 | 97.9% | −0.8 |
| Q4 FY2017 | Dec 31, 2017 | 98.4% | −1.6 |
| Q3 FY2017 | Sep 30, 2017 | 97.8% | −2.2 |
| Q2 FY2017 | Jun 30, 2017 | 95.6% | – |
| Q1 FY2017 | Mar 31, 2017 | 98.7% | – |
| Q4 FY2016 | Dec 31, 2016 | 100.0% | – |
| Q3 FY2016 | Sep 30, 2016 | 100.0% | – |
See a number that looks wrong?